Single-dose attenuated Vesiculovax vaccines protect primates against Ebola Makona virus.
about
Filoviruses: One of These Things is (not) Like the OtherParticulate delivery systems for vaccination against bioterrorism agents and emerging infectious pathogensA Perspective on the Development of Plant-Made Vaccines in the Fight against Ebola VirusPost-exposure treatment of non-human primates lethally infected with Ebola virus with EBOTAb, a purified ovine IgG product.First-in-Human Evaluation of the Safety and Immunogenicity of a Recombinant Vesicular Stomatitis Virus Human Immunodeficiency Virus-1 gag Vaccine (HVTN 090).Considerations in the Use of Nonhuman Primate Models of Ebola Virus and Marburg Virus Infection.The Role of a National Biocontainment Laboratory in Emergencies.Ebola Virus Infections in Nonhuman Primates Are Temporally Influenced by Glycoprotein Poly-U Editing Site Populations in the Exposure Material.Oral and Conjunctival Exposure of Nonhuman Primates to Low Doses of Ebola Makona VirusBoHV-4-based vector delivering Ebola virus surface glycoprotein.Vaccine platforms to control Lassa fever.Ebola virus disease candidate vaccines under evaluation in clinical trials.Ebola virus vaccines - reality or fiction?Integrated Computational Approach for Virtual Hit Identification against Ebola Viral Proteins VP35 and VP40.Recombinant Isfahan Virus and Vesicular Stomatitis Virus Vaccine Vectors Provide Durable, Multivalent, Single-Dose Protection against Lethal Alphavirus Challenge.Pathogenicity Comparison Between the Kikwit and Makona Ebola Virus Variants in Rhesus MacaquesNovel viral vectors in infectious diseases.Attenuated Human Parainfluenza Virus Type 1 Expressing Ebola Virus Glycoprotein GP Administered Intranasally Is Immunogenic in African Green Monkeys.Passive Immunotherapy: Assessment of Convalescent Serum Against Ebola Virus Makona Infection in Nonhuman Primates.Efficacy of Vesicular Stomatitis Virus-Ebola Virus Postexposure Treatment in Rhesus Macaques Infected With Ebola Virus Makona.Live virus vaccines based on a vesicular stomatitis virus (VSV) backbone: Standardized template with key considerations for a risk/benefit assessment.Single Dose Trivalent Vesiculovax Vaccine Protects Macaques from Lethal Ebolavirus and Marburgvirus Challenge.From bench to almost bedside: the long road to a licensed Ebola virus vaccine.Assessment of the ability of V920 recombinant vesicular stomatitis-Zaire ebolavirus vaccine to replicate in relevant arthropod cell cultures and vector species.Haiku: New paradigm for the reverse genetics of emerging RNA viruses.Distinct Immunogenicity and Efficacy of Poxvirus-based Vaccine Candidates against Ebola Virus expressing GP and VP40 Proteins.Advanced model systems and tools for basic and translational human immunology
P2860
Q26783063-8F6C9286-FBC1-422F-8E56-916C3C5562CEQ27011190-0B25E8F2-AB41-4208-BDD2-B64C3134E492Q30235073-2037F96A-9778-4959-B4DA-1593D4DD57BBQ33826350-B85230D0-98F9-4E36-9D35-3E775FF361DAQ35858437-853868B7-478A-49E4-A4D8-E34DC34F684AQ36043284-7E83CC8E-A6CD-44E6-A0CA-8BE2E6285D28Q36092115-47645F49-1E70-422C-ACED-5CEDD9B5302DQ36403500-899515E3-9328-4F0E-8B1C-E21D6EA658D8Q37310749-8A4321AB-D865-454A-BCAF-AB837D6299F6Q37436625-49A834A7-12CD-41E5-8CA6-3C59C9388AEDQ38823264-A7DFAE59-072F-4802-9B3E-AF4A709F5A02Q38830109-049A7886-5363-4C4C-AC53-F55133D0A409Q38881265-DE71A3DF-DD90-409C-AFB0-BD6EEE5A99B4Q39216411-20F7EDD6-6BA6-45CC-AC88-AF2455FB7E5AQ39294255-18BB63D9-2BD6-4B10-A092-A55AB6133328Q39601175-2FE2146E-F1C8-4C09-B1D4-9C4887EA99C4Q40059020-95B66D9D-36A5-4405-94A2-08F22B6F1BF7Q40067156-6406633F-4513-4556-BD67-EC112FA8B4EDQ40091054-C2F62323-D51A-4C21-840E-ED6CE09FB7D0Q40093846-7BE0895B-E170-4A3E-A48F-C93346A6682BQ40619713-38AED3C2-2014-42B2-9187-423C74D1AFD3Q44106241-5910DDDF-56C4-4A3D-8A07-AB6FE626B041Q44106264-55E50AE4-0F95-4D24-AFD8-9E7A41BEEBD3Q46247851-32DD6E14-9954-44FB-9BD4-92303F58775DQ50041776-3540C78B-9ABA-451C-A1AB-15C5E9E09FE9Q51784219-0DF02F6C-E191-4EB7-A336-17BC340C8A2EQ59126043-8182ED72-82CC-4BDA-B390-83883234C03A
P2860
Single-dose attenuated Vesiculovax vaccines protect primates against Ebola Makona virus.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Single-dose attenuated Vesiculovax vaccines protect primates against Ebola Makona virus.
@ast
Single-dose attenuated Vesiculovax vaccines protect primates against Ebola Makona virus.
@en
type
label
Single-dose attenuated Vesiculovax vaccines protect primates against Ebola Makona virus.
@ast
Single-dose attenuated Vesiculovax vaccines protect primates against Ebola Makona virus.
@en
prefLabel
Single-dose attenuated Vesiculovax vaccines protect primates against Ebola Makona virus.
@ast
Single-dose attenuated Vesiculovax vaccines protect primates against Ebola Makona virus.
@en
P2093
P2860
P921
P356
P1433
P1476
Single-dose attenuated Vesiculovax vaccines protect primates against Ebola Makona virus.
@en
P2093
Ayuko Ota-Setlik
Chad E Mire
David K Clarke
Demetrius Matassov
Joan B Geisbert
John H Eldridge
Karla A Fenton
Krystle N Agans
Michael A Egan
P2860
P2888
P304
P356
10.1038/NATURE14428
P407
P577
2015-04-08T00:00:00Z
P5875
P6179
1049585947